US 12,329,583 B2
Method for providing information for choosing breast cancer treatment method by using breast cancer ultrasonic image and gene information
Bo Kyoung Seo, Seoul (KR); Mi-Ryung Han, Seoul (KR); and Ah Young Park, Gyeonggi-do (KR)
Assigned to KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION, Seoul (KR); and CHA UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, Gyeonggi-do (KR)
Appl. No. 17/771,939
Filed by KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION, Seoul (KR); and CHA UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, Gyeonggi-do (KR)
PCT Filed Sep. 18, 2020, PCT No. PCT/KR2020/012592
§ 371(c)(1), (2) Date Apr. 26, 2022,
PCT Pub. No. WO2021/054752, PCT Pub. Date Mar. 25, 2021.
Claims priority of application No. 10-2019-0116230 (KR), filed on Sep. 20, 2019.
Prior Publication US 2022/0401077 A1, Dec. 22, 2022
Int. Cl. A61B 8/00 (2006.01); A61B 8/08 (2006.01)
CPC A61B 8/5223 (2013.01) [A61B 8/0825 (2013.01); A61B 8/0891 (2013.01); A61B 8/481 (2013.01)] 3 Claims
OG exemplary drawing
 
1. A method for providing information for choosing a breast cancer therapy by using an ultrasound image of breast cancer, the method comprising:
a phenotype determination step of determining a phenotype of a breast tumor by using an ultrasound image;
a gene information determination step of determining at least one gene information related to the breast cancer by using the phenotype of the breast tumor; and
a therapy determination step of determining an individual breast cancer therapy by correlating the determined at least one gene information with gene information associated with the breast cancer therapy,
wherein the ultrasound image is a B-mode ultrasound image,
wherein the phenotype determined through the B-mode ultrasound image includes size, shape, orientation, margin, and calcifications of the breast tumor,
wherein the size is related to at least one gene selected from the group consisting of MIR941-1, IGLV6-57, HIST1H1B, HIST1H31, ADH1B, PLIN4, and LUZP6;
the shape is related to at least one gene selected from the group consisting of MIR941-1, ZFP36L1, SNHG9, H2AFY2, POTEI, UBE2Q2L, FABP7, IGHV3-43, IGKJ5, and IGKJ2;
the orientation is related to at least one gene selected from the group consisting of TFF1, AREG, AGR3, TFF3, LINC00993, IGKV2-28, IGLV1-51, IGHV3-73, IGKV3-20, IGLV2-14, IGKV1-12, IGHV4-61, IGKV3D-15, IGHV1-3, IGHV4-4, IGHV1-18, IGHV4-34, IGHV3-74, CALML5, IGHJ5, and IGKJ2;
the margin is related to HLA-C gene; and
the calcifications are related to at least one gene selected from the group consisting of CALML3, HIST1H4F, IGHV4OR15-8, CCL19, and IGLV8-61.